WVE vs. RYTM, KRYS, CYTK, ZLAB, PTCT, MRUS, ACLX, ACAD, SWTX, and RARE
Should you be buying WAVE Life Sciences stock or one of its competitors? The main competitors of WAVE Life Sciences include Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.
WAVE Life Sciences vs. Its Competitors
WAVE Life Sciences (NASDAQ:WVE) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
89.7% of WAVE Life Sciences shares are owned by institutional investors. 24.0% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
WAVE Life Sciences has a beta of -1.01, meaning that its share price is 201% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500.
In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 5 mentions for Rhythm Pharmaceuticals and 2 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.34 indicating that WAVE Life Sciences is being referred to more favorably in the media.
WAVE Life Sciences presently has a consensus target price of $20.50, suggesting a potential upside of 194.12%. Rhythm Pharmaceuticals has a consensus target price of $77.31, suggesting a potential upside of 17.53%. Given WAVE Life Sciences' higher possible upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Rhythm Pharmaceuticals.
WAVE Life Sciences has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -123.26%. WAVE Life Sciences' return on equity of -86.49% beat Rhythm Pharmaceuticals' return on equity.
WAVE Life Sciences has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
WAVE Life Sciences beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get WAVE Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
WAVE Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 7/5/2025 by MarketBeat.com Staff
Free WVE Stock Alerts